The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the privotal trials.

[Correction Notice: An erratum for this article was reported in Vol 107(2-3) of Schizophrenia Research (see record [rid]2009-01129-038[/rid]). The authors regret that in the published article, a coding error has led to an incorrect value for the change in PANSS General Psychopathology subscale being inadvertently published. On page 213, under the heading “3.6 Effect sizes” the sentence should read as follows: “Potentially clinically significant effect sizes for aripiprazole versus placebo were seen for PANSS Total, PANSS Positive, and PANSS General Psychopathology (0.57, 0.55 and 0.52 at Week 4, respectively).” The values in (Fig. 1a and 1b) have also been updated with the correct change from baseline values. The corrected figures are given in the erratum.]

OBJECTIVE:

To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder.

METHODS:

Data were pooled from five, 4-6-week acute studies. PANSS Total, Positive, Negative, and General Psychopathology Subscale improvements were analyzed, as well as all 30 individual PANSS items.

RESULTS:

Aripiprazole had statistically significant decreases versus placebo on PANSS subscales at Week 4, similar to those seen with haloperidol. Aripiprazole-treated patients also showed significant decreases versus placebo in 26 of the 30 PANSS items (all p < 0.05).

CONCLUSION:

Aripiprazole demonstrates statistically and clinically significant efficacy across a range of symptoms in schizophrenia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)